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Objectives: This study aimed to evaluate cost-related trends associ-
ated with the management of critical limb ischemia (CLI) in a national
United States sample.
Methods: All patients with a primary diagnosis code of CLI were
identiﬁed from the 2001 to 2011 National Inpatient Sample. Demo-
graphics, CLI management, comorbidities, complications (bleeding, surgi-
cal site infection [SSI]), length of stay, and median in-hospital costs were
reviewed. Statistical analysis was completed using descriptive statistics, the
Student t-test, and the Fisher exact test. Costs are reported in 2011 United
States dollars corrected using the Consumer Price Index.
Results: From 2001 to 2011, 92,160 patients underwent open or
endovascular management for CLI. Table I depicts the incidence and
complications of CLI patients managed with endovascular versus open
techniques from 2001 to 2011. Overall, costs to treat CLI increased by
63%, from $12,560 in 2001 to $20,517 in 2011 (P < .001 in trend anal-
ysis). Endovascular interventions were 20% more expensive compared with
open surgery ($19,566 vs $16,337; P < .001). Age, gender, and insurance
status did not affect the cost of care. From 2001 to 2011, increases were
documented in the number of patient comorbidities (from 7.56 to 12.40),
procedures (from 3.46 to 4.96), and percentage of endovascular cases
(from 13.4% to 27.4%), accounting for a 6% annual increase in the total
cost even with a decreased mean length of stay (8.5 to 6.5 days). Patients
with SSI (1276 [1.4%]) had total costs 83% greater than patients without
SSI ($30,949 vs $16,939; P < .001), and patients who developed
bleeding complications (4131 [4.5%]) and required a return to the oper-
ating room had total costs 41% greater than nonbleeding patients
($23,779 vs $16,821; P < .001). Overall, there was a 32% decrease in
SSI but unchanged rates of bleeding complications in this time period.
Conclusions: The cost of CLI has increased signiﬁcantly during the
last decade. An increasing trend is seen in the number of patient comorbid-
ities and in the number of CLI patients managed endovascularly. The costs
of treating preventable complications, including SSI and bleeding, signiﬁ-
cantly drive the overall cost of managing patients with CLI.
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Year 2001 2002 2003 2004 2005
Open procedure
No. 7343 6995 6301 6321 6258
SSI 119 141 103 118 103
Bleeding 326 304 265 288 249
Cost ($) 12,490 13,576 14,702 15,236 15,933
Endovascular procedure
No. 1137 1176 1442 1771 1873
SSI 13 15 13 19 15
Bleeding 58 78 75 109 108
Cost ($) 13,097 13,688 15,694 17,277 17,292
SSI, Surgical site infection.Superﬁcial Femoral Artery Use for Percutaneous Endovascular Aortic
Aneurysm Repair
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Objectives: Percutaneous endovascular aortic aneurysm repair
(PEVAR) through the common femoral artery (CFA) is a safe alternative
to traditional open CFA exposure. Technical success is reduced if the
CFA is an inappropriate percutaneous target. During the last 5 years we
have routinely used the superﬁcial femoral artery (SFA) for EVAR cutdown
and have noted that the SFA may be a superior target for percutaneous ac-
cess in a minority of patients. Despite this, its use for PEVAR has not been
reported to date. We present a case series of 10 patients who underwent
PEVAR that used one or both SFAs.
Methods: We reviewed all PEVAR procedures at our two institutions
since October 2012, identifying all patients in whom one or both SFAs were
used for endograft delivery. We reviewed intraoperative ﬁndings and the last
available follow-up computed tomography scans to assess indication, tech-
nical success, and long-term patency.
Results: Of 79 PEVAR procedures that were recorded, 10
involved one or both SFAs. In total, 13 SFAs were used: six for the
introduction of the main body component (size range 18F-20F) and
seven for the introduction of the limb (14F-16F) (Table). There were
two failures, both of which involved a limb component. One failure,
in a somewhat diseased artery, was due to vessel occlusion at procedure
completion. The other had an active bleed at the time of the initial
sheath insertion that required cutdown. In the remaining six main
body procedures and ﬁve limb introduction procedures, intraoperative
completion duplex imaging conﬁrmed successful closure and vessel
patency. All patients maintained patency of the SFA at latest follow-
up computed tomography scan (range, 1-13 months; median, 8
months). Indications for use of the SFA instead of CFA included
obesity (depth to CFA >3.5-4.0 cm from the skin), CFA anterior
wall calciﬁcation or mural thrombus, scarring from previous CFA sur-
gery, tortuous iliac arteries (easier to advance closure device an
adequate length when starting more distally), and high bifurcation of
the CFA.
Conclusions: This preliminary evaluation suggests that the SFA may
be used for up to 20F access with PEVAR when the CFA is judged inap-
propriate. Completion duplex is recommended to assess patency. Further
studies will be required to conﬁrm these ﬁndings.
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2006 2007 2008 2009 2010 2011
7052 6960 7676 7035 6843 7700
101 121 114 102 89 100
278 296 368 280 297 323
15,998 16,928 18,047 18,313 18,874 19,616
2208 2607 2978 2657 2643 2899
26 13 13 18 18 25
127 143 130 111 121 143
18,464 19,874 20,406 22,716 23,082 22,906
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